See more : Shenzhen Aoni Electronic Co., Ltd. (301189.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Black Diamond Therapeutics, Inc. (BDTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Diamond Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Beijing Baolande Software Corporation (688058.SS) Income Statement Analysis – Financial Results
- Ninestar Corporation (002180.SZ) Income Statement Analysis – Financial Results
- T-Flex Techvest PCB Co., Ltd. (3276.TWO) Income Statement Analysis – Financial Results
- Aravive, Inc. (ARAV) Income Statement Analysis – Financial Results
- Media Pal Holdings, Corp. (MPHD) Income Statement Analysis – Financial Results
Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| Gross Profit | -437.00K | -3.24M | -2.22M | -600.00K | -47.00K | -44.00K | -24.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 59.35M | 64.44M | 96.83M | 48.21M | 21.75M | 6.95M | 3.45M |
| General & Administrative | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Other Expenses | 0.00 | -354.00K | -2.19M | -1.72M | 6.00K | -16.00K | -6.00K |
| Operating Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Cost & Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Interest Income | 1.92M | 2.03M | 3.46M | 4.04M | 461.00K | 4.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 65.00K |
| Depreciation & Amortization | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| EBITDA | -86.02M | -92.32M | -126.67M | -66.65M | -29.29M | -8.89M | -4.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -86.46M | -92.83M | -126.87M | -69.57M | -8.90M | -8.90M | -4.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.02M | 1.66M | 1.28M | 2.32M | -5.93M | -27.00K | -483.00K |
| Income Before Tax | -82.44M | -88.92M | -125.60M | -67.25M | -35.26M | -8.93M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.40M | -2.39M | -1.78M | 5.89M | -27.00K | 59.00K |
| Net Income | -82.44M | -84.52M | -123.20M | -65.48M | -41.14M | -8.93M | -4.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
| Weighted Avg Shares Out (Dil) | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
Hot Penny Stocks to Add to Your Mid-January Watchlist
Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations
Source: https://incomestatements.info
Category: Stock Reports